Company Vaxcyte, Inc.

Equities

PCVX

US92243G1085

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-10 pm EDT			5-day change	1st Jan Change
65.19 ^USD	-0.58%		-1.17%	+3.81%

May. 08	Vaxcyte, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Apr. 25	Vaxcyte Insider Sold Shares Worth $928,845, According to a Recent SEC Filing	MT

Vaxcyte Inc. is a clinical-stage vaccine company. It is engaged in developing a spectrum conjugate and protein vaccines to prevent or treat bacterial infectious diseases. Its lead candidate, VAX-24, is a Phase III-ready 24-valent, carrier-sparing pneumococcal conjugate vaccine (PCV) being developed for the prevention of invasive pneumococcal disease (IPD). VAX-31, the Companyâs next generation 31-valent PCV is developed for the prevention of IPD in adults. Its pipeline also includes VAX-A1, VAX-PG, and VAX-GI. VAX-A1, a novel conjugate vaccine candidate designed to prevent disease caused by Group A Streptococcus (Group A Strep). VAX-PG, a novel protein vaccine candidate targeting pathogen responsible for periodontitis, a chronic oral inflammatory disease. VAX-GI, a novel preclinical vaccine candidate being developed as a preventative treatment for dysentery and shigellosis. Its technology platform includes advanced chemistry and the XpressCF cell-free protein synthesis platform.

Number of employees: 254

Managers	Title	Age	Since
Jeff Fairman FOU	Founder	60	13-05-26
Grant Pickering FOU	Founder	56	13-05-26
Andrew Guggenhime DFI	Director of Finance/CFO	55	20-04-30
Jakub Simon CTO	Chief Tech/Sci/R&D Officer	-	22-10-10
Mikhail Eydelman CMP	Compliance Officer	43	22-03-31
James Wassil COO	Chief Operating Officer	54	19-11-30
Janet Graesser IRC	Investor Relations Contact	-	21-03-31
Elvia Cowan PRN	Corporate Officer/Principal	51	22-06-30
Whitney Jones HRO	Human Resources Officer	-	Jan. 15
Harpreet Dhaliwal PRN	Corporate Officer/Principal	-	21-09-28

Members of the board	Title	Age	Since
Grant Pickering FOU	Founder	56	13-05-26
Anne Drapeau BRD	Director/Board Member	57	21-09-15
Heath Lukatch BRD	Director/Board Member	56	18-04-30
K. Hirth BRD	Director/Board Member	72	16-08-31
Halley Gilbert BRD	Director/Board Member	54	20-03-31
Carlos Paya CHM	Chairman	65	21-10-26
Teri Loxam BRD	Director/Board Member	52	21-09-15
Jacks Lee BRD	Director/Board Member	60	Nov. 26

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	108,795,188	107,055,055 ( 98.40 %)	0	98.40 %

Name	Equities	%	Valuation
Fidelity Management & Research Co. LLC 13.11 %	14,213,365	13.11 %	971 M $
Vanguard Fiduciary Trust Co. 8.982 %	9,737,254	8.982 %	665 M $
BlackRock Advisors LLC 8.132 %	8,816,135	8.132 %	602 M $
RA Capital Management LP 7.279 %	7,891,254	7.279 %	539 M $
Janus Henderson Investors US LLC 6.440 %	6,981,376	6.440 %	477 M $
Wellington Management Co. LLP 4.088 %	4,431,920	4.088 %	303 M $
Capital Research & Management Co. (Global Investors) 3.173 %	3,440,107	3.173 %	235 M $
STATE STREET CORPORATION 3.127 %	3,389,528	3.127 %	232 M $
T. Rowe Price International Ltd. 2.470 %	2,677,822	2.470 %	183 M $
Geode Capital Management LLC 1.820 %	1,973,506	1.820 %	135 M $

Vaxcyte, Inc.

825 Industrial Road Suite 300

94070, San Carlos

+650 837 0111

http://www.vaxcyte.com

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

65.19 USD

Average target price

103.1 USD

Spread / Average Target

+58.22%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
VAXCYTE, INC.	+3.81%	7.09B
VERTEX PHARMACEUTICALS INCORPORATED	+3.91%	109B
REGENERON PHARMACEUTICALS, INC.	+10.87%	105B
ARGENX SE	+1.28%	22.25B
BIONTECH SE	-13.14%	22.09B
GENMAB A/S	-7.05%	18.68B
WUXI APPTEC CO., LTD.	-38.36%	17.58B
BEIGENE, LTD.	-10.66%	16.85B
NEUROCRINE BIOSCIENCES, INC.	+3.75%	13.76B
SAREPTA THERAPEUTICS, INC.	+36.70%	12.46B

Bio Therapeutic Drugs